DEPENDENCE OF LEVELS OF BONE METABOLISM MARKERS ON THE STAGE OF MEDICATION-RELATED OSTEONECROSIS OF THE JAWS-Reference-Cited by-同舟云学术

DEPENDENCE OF LEVELS OF BONE METABOLISM MARKERS ON THE STAGE OF MEDICATION-RELATED OSTEONECROSIS OF THE JAWS

Published:2023-11-30 Issue:3 Volume:19 Page:75-79
ISSN:2077-7566
Container-title:Actual problems in dentistry
language:en
Short-container-title:

Author:

Spevak Elena¹²^ORCID,Christoforando Dmitry²¹,Gandylyan Kristina²,Dolgalev Aleksandr²,Eliseeva Evgeniya²

Affiliation:

1. City Clinical Emergency Hospital

2. Stavropol State Medical University

Abstract

Subject. The stages of medication-related osteonecrosis of the jaws (MRONJ) are an important criterion for choosing treatment tactics, while laboratory diagnosis of the stages of MRONJ has not been developed. The aim of the study is to analyze the dependence of the levels of bone metabolic markers (BMM) on the stage of the disease in patients with MRONJ. Methodology. The study included 48 cancer patients with osteonecrosis of the jaws while taking osteomodifying agents (OMA) with stabilization of the underlying disease. The activity of osteosynthesis was assessed by the level of osteocalcin (OC), osteoresorption – C-terminal telopeptide (CTX) – in the blood serum before treatment. The stage of MRONJ was established according to the classification developed at the Department of Surgical Dentistry and Maxillofacial Surgery of Stavropol State Medical University (2017). The levels of BMM indicators were compared for clinically significant stages (1, 2, 3) using the Kruskal–Wallis test for p < 0.05. Results. Stage 1 MRONJ was established in 17 (35.42%) patients, stage 2 – in 25 (52.08%) patients, stage 3 – in 6 (12.5%) patients. The average values of BMM indicators were: in patients with stage 1 – OK – 14.65 (10.5;17.5) ng/ml, CTX – 0.289 (0.172;0.351); with stage 2 OK – 10 (8.74;11) ng/ml, CTX – 0.137 (0.09;0.18); with stage 3 – OK – 15.5 (14;21) ng/ml, CTX – 0.476 (0.353;0.633). The average OC values were statistically significantly different in groups of patients with different stages of MRONJ (H = 14.13; p = 0.00085; p < 0.05), as were the STX values (H = 22.3; p = 0.00001; p < 0.05). At the same time, the average levels of both BMM in patients with stage 2 were lower than in patients with stage 1, and their highest level was recorded in stage 3 of the process. Conclusions. A significant (p < 0.05) relationship was established between the levels of OC and CTX and the stage of MRONJ: the maximum values were recorded at the third stage, the minimum at the second and intermediate at the first.

Publisher

TIRAZH Publishing House

Subject

General Medicine

Reference17 articles.

1. Di Fede O., Panzarella V., Mauceri R., Fusco V., Bedogni A., Lo Muzio L., SIPMO ONJ Board, Campisi G. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention // Biomed. Res. Int. – 2018;2018:2684924. doi: 10.1155/2018/2684924., Di Fede O., Panzarella V., Mauceri R., Fusco V., Bedogni A., Lo Muzio L., SIPMO ONJ Board, Campisi G. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. Biomed. Res. Int. 2018; 2018: 2684924. doi: 10.1155/2018/2684924.

2. Ruggiero S.L., Dodson T.B., Aghaloo T., Carlson E.R., Ward B.B., Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update // J. Oral Maxillofac. Surg. – 2022;80(5):920-943. doi: 10.1016/j.joms.2022.02.008., Ruggiero S.L., Dodson T.B., Aghaloo T., Carlson E.R., Ward B.B., Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J. Oral Maxillofac. Surg. 2022; 80(5): 920-943. doi: 10.1016/j.joms.2022.02.008.

3. Limones A., Sáez-Alcaide L.M., Díaz-Parreño S.A., Helm A., Bornstein M.M., Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis // Med Oral Patol Oral Cir Bucal. – 2020;25(3):326-336. doi: 10.4317/medoral.23324., Limones A., Sáez-Alcaide L.M., Díaz-Parreño S.A., Helm A., Bornstein M.M., Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020; 25 (3): 326-336. doi: 10.4317/medoral.23324.

4. King R., Tanna N., Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review // Oral Surg. Oral Med. Oral Pathol. Oral Radiol. – 2019;127(4):289-299. doi: 10.1016/j.oooo.2018.11.012., King R., Tanna N., Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2019; 127(4): 289-299. doi: 10.1016/j.oooo.2018.11.012.

5. Ahdi H.S., Wichelmann T.A., Pandravada S., Ehrenpreis E.D. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS) // BMC Pharmacol Toxicol. – 2023;6;24(1):15. doi: 10.1186/s40360-023-00657-y., Ahdi HS, Wichelmann TA, Pandravada S, Ehrenpreis ED. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS). BMC Pharmacol Toxicol. 2023 Mar 6;24(1):15. doi: 10.1186/s40360-023-00657-y.